MedTrace Logo

Penetration of Moxifloxacin Into Liver Tissue of Patients Undergoing Liver Resection.

NCT01302951 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2011-02-24

No results posted yet for this study

Summary

The aim of the study is to provide data on the pharmacokinetics (PK) of moxifloxacin (MXF) in serum and liver tissue of patients undergoing liver resection due to primary or secondary tumor of the liver.

Conditions

  • Side-effect of Antibiotic

Interventions

DRUG

Moxifloxacin 400 mg

The patients receive MXF 400 mg as one hour intravenous infusion at randomized timed intervals prior to liver resection.

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • University Hospital, Saarland

    lead OTHER

Principal Investigators

  • Martin K Schilling, MD · University hospital of the Saarland

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • Germany

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01302951 on ClinicalTrials.gov